Press Release

HemoVoid™ Advances Multi-omic Study of Thalassemia Severity

MONMOUTH JUNCTION, NJ, February 17, 2026– An article let by researchers from The University of Burdwan, India utilized HemoVoid™ enrichment in a multi-omic study of thalassemia. The citation is: Mitra, Nibedita, et al. "Multi-omics analysis of red blood cells reveals thalassemia severity beyond globin gene mutations." Blood Advances (2026): bloodadvances-2025016677.

Thalassemia is classified as transfusion-dependent (TDT), requiring regular transfusions, and non-transfusion-dependent (NTDT), which follows a milder clinical course. This study aims to identify dysregulated molecular pathways in red blood cells contributing to thalassemia severity. RNA sequencing and proteome analysis were conducted on isolated RBCs, through Novaseq and Orbitrap MS platform respectively. For proteome analysis, the article states “A 75 µL RBC suspension was used for protein extraction with RIPA buffer (Thermo Fisher Scientific), and hemoglobin was depleted using the HemoVoid Kit (Biotech Support Group, Cat. No. HVB-MS10)”.

TDT samples exhibited higher protein-to-transcript (PTRs) for ferroptosis-related proteins (FTH1, FTL, HMOX1) and lower PTRs for autophagy genes, suggesting impaired cellular recycling and enhanced oxidative cell death. PTR analysis showed reduced cytoskeletal (ankyrin, spectrin) expression, elevated chaperone activity, ferroptosis markers (FTH1, FTL, HMOX1), and suppressed autophagy. Collectively, these multilayered alterations—splicing dysfunction, post-transcriptional deregulation, ferroptosis, autophagy suppression, oxidative stress, and cytoskeletal fragility—underlie the greater disease severity observed in TDT compared with NTDT.

“This is an excellent study demonstrating how HemoVoid™ can be used in a multi-omic study comparing different disease severities. The HemoVoid™ product used in this study is one of many beads derived from our unique NRicher™ surface chemistry platform. With HemoVoid™ enrichment, the study was able to differentiate different patient cohorts by protein-to-transcript (PTR) associations. stated Dr. Swapan Roy, President and Founder of Biotech Support Group.

For more information on HemoVoid™ LC-MS On-Bead, visit:

https://www.biotechsupportgroup.com/HemoVoid-LC-MS...

For more information of all of our Hemoglobin removal products, visit:

https://www.biotechsupportgroup.com/Hemoglobin-Removal-s/312.htm

For more information on our NRicher™ bead chemistry platform, visit:

https://www.biotechsupportgroup.com/category-s/340.htm

About Biotech Support Group LLC
Biotech Support Group develops innovative sample preparation technologies that address the emerging needs of proteomics, biomarker discovery, and personalized medicine. Flagship products include Cleanascite™ for lipid removal, AlbuVoid™ and AlbuSorb™ PLUS for serum protein depletion, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NRicher™ for low abundance, family specific, and targeted proteome enrichment. These products support translational research by simplifying workflows and improving sample quality for downstream analysis.

For Business Development Inquiries:
Matthew Kuruc
Phone: 732-274-2866
Email: [email protected]

Keywords: HemoVoid™, Hemoglobin depletion, Hemoglobin removal, Thalassemia, Red Blood Cell proteomics, protein-to-transcript (PTR),